Beta Bionics, J.B. Hunt Transport And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures rose, but Beta Bionics fell 7.1% after pricing a stock offering; several other stocks also declined in premarket trading.
Stocks · News reference
Top 3 Health Care Stocks That Could Blast Off This Month
The health care sector's oversold stocks present buying opportunities for undervalued companies. RSI compares stock strength on up and down days, with an RSI below 30 considered oversold.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Beyond Ozempic: Novo Nordisk Plots Next Decade Growth with Bigger Pipeline, Slimmer Workforce
Novo Nordisk targets 2026-2030 growth, and unveils Phase 3 CagriSema results beating Eli Lilly's tirzepatide in weight loss trials.
Trex Bio Files For Initial Public Offering; Applies To List Common Stock On Nasdaq Under Symbol 'TRXB'; Eli Lilly Indicates Interest In Purchasing Up To 19.9% Of Trex Bio Common Stock; Says J.P. Morgan, Evercore ISI, Cantor, Stifel, Wedbush PacGrow Are Underwriters To IPO
https://www.sec.gov/Archives/edgar/data/2139097/000119312526395671/ck0002139097-20260918.htm
Eli Lilly Announces FDA Approval Of Inluriyo In Combination With Verzenio For Treatment Of Adults With ER+, HER2–, ESR1-Mutated Locally Advanced Or Metastatic Breast Cancer
Inluriyo plus Verzenio delivers proven clinical benefit after the evidence-based practice of maximizing initial treatment with an aromatase inhibitor, with or without a CDK4/6 inhibitor In the Phase 3 EMBER-3 trial,
This $3 Biotech Could Be Worth $11.45, Analyst Says
William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.
Avantor Broadens RIM Single-Use Bioprocessing Reach in APAC
Avantor has expanded its RIM single-use bioprocessing portfolio across the Asia Pacific region with local manufacturing in China. The expansion aims to improve supply reliability and customization for regional biopharma customers. The company's Bioscience & Medtech Products segment showed double-digit order growth and a 1.1x book-to-bill ratio in Q2 2026, supporting long-term bioprocessing growth.